Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma

被引:130
|
作者
Tremosini, Silvia [1 ]
Forner, Alejandro [1 ,2 ]
Boix, Loreto [1 ,2 ]
Vilana, Ramon [2 ,3 ]
Bianchi, Luis [2 ,3 ]
Reig, Maria [1 ,2 ]
Rimola, Jordi [2 ,3 ]
Rodriguez-Lope, Carlos [1 ]
Ayuso, Carmen [2 ,3 ]
Sole, Manel [2 ,4 ]
Bruix, Jordi [1 ,2 ]
机构
[1] Univ Barcelona, Hosp Clin Barcelona, Barcelona Clin Liver Canc BCLC Grp, Liver Unit,IDIBAPS, E-08007 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, CIBERehd, E-08007 Barcelona, Spain
[3] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Radiol Dept,Barcelona Clin Liver Canc BCLC Grp, E-08007 Barcelona, Spain
[4] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Pathol Dept,Barcelona Clin Liver Canc BCLC Grp, E-08007 Barcelona, Spain
关键词
CIRRHOSIS; EXPRESSION; LESIONS; NODULES; MARKER; HSP70; HEPATOCARCINOGENESIS; SERUM; GPC3;
D O I
10.1136/gutjnl-2011-301862
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims Conventional pathological analysis fails to achieve sufficient sensitivity and specificity for the diagnosis of hepatocellular carcinoma (HCC) in small nodules. Immunohistochemical staining for glypican 3 (GPC3), heat shock protein 70 (HSP70) and glutamine synthetase (GS) has been suggested to allow a confident diagnosis but no prospective study has established the diagnostic accuracy of this approach. The aim of this study is to assess prospectively the diagnostic accuracy of a panel of markers (GPC3, HSP70, GS) for the diagnosis of HCC in patients with cirrhosis with a small (5-20 mm) nodule detected by ultrasound screening. Methods Sixty patients with cirrhosis with a single nodule 5-20 mm newly detected by ultrasound were included in the study. Contrast-enhanced ultrasound, magnetic resonance and fine needle biopsy of the nodule (gold standard) were performed; the biopsy was repeated in case of diagnostic failures. Three consecutive sections of the first biopsy sample with meaningful material were stained with antibodies against GPC3, HSP70 and GS. Results Forty patients were diagnosed with HCC. The sensitivity and specificity for HCC diagnosis were: GPC3 57.5% and 95%, HSP70 57.5% and 85%, GS 50% and 90%, respectively. The sensitivity and specificity of the different combinations were: GPC3+HSP70 40% and 100%; GPC3+GS 35% and 100%; HSP70+GS 35% and 100%; GPC3+HSP70+GS 25% and 100%. When at least two of the markers were positive (regardless of which), the sensitivity and specificity were 60% and 100%, respectively. Conventional pathological analysis yielded three false negative results, but the addition of this panel only correctly classified one of these cases as HCC. Conclusion These data within a prospective study establish the clinical usefulness of this panel of markers for the diagnosis of early HCC. However, the panel only slightly increases the diagnostic accuracy in an expert setting.
引用
收藏
页码:1481 / 1487
页数:7
相关论文
共 23 条
  • [21] Acceleration of hepatocellular energy by idebenone during early reperfusion after cold preservation ameliorates heat shock protein 70 gene expression in a pig liver model
    Schutz, E
    Wieland, E
    Heine, L
    Hensel, A
    Schmiedl, A
    Armstrong, VW
    Richter, J
    SchuffWerner, P
    Gunther, E
    Oellerich, M
    TRANSPLANTATION, 1997, 64 (06) : 901 - 907
  • [22] Correction to: Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial
    Hiroto Matsui
    Shoichi Hazama
    Masao Nakajima
    Ming Xu
    Satoshi Matsukuma
    Yukio Tokumitsu
    Yoshitaro Shindo
    Shinobu Tomochika
    Shin Yoshida
    Michihisa Iida
    Nobuaki Suzuki
    Shigeru Takeda
    Shigefumi Yoshino
    Tomio Ueno
    Masaaki Oka
    Hiroaki Nagano
    Cancer Immunology, Immunotherapy, 2021, 70 : 959 - 959
  • [23] Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial (Oct, 10.1007/s00262-020-02737-y, 2020)
    Matsui, Hiroto
    Hazama, Shoichi
    Nakajima, Masao
    Xu, Ming
    Matsukuma, Satoshi
    Tokumitsu, Yukio
    Shindo, Yoshitaro
    Tomochika, Shinobu
    Yoshida, Shin
    Iida, Michihisa
    Suzuki, Nobuaki
    Takeda, Shigeru
    Yoshino, Shigefumi
    Ueno, Tomio
    Oka, Masaaki
    Nagano, Hiroaki
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (04) : 959 - 959